Evaluating Clinical Sequelae of the Carbapenem-Valproate Interaction: A Retrospective Analysis

• Published in: Open forum infectious diseases Vol. 11; no. 3; p. ofae130
• Main Authors: Petrucelli, Nick, Hayes, Bryan D, Shelat, Nidhi, Elshaboury, Ramy H, Pearson, Jeffrey C, Koehl, Jennifer L
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.03.2024
• Subjects: interaction; valproate; carbapenem; seizure
• ISSN: 2328-8957; 2328-8957
• DOI: 10.1093/ofid/ofae130

Abstract Background Previous studies identified a rapid decrease in valproate serum concentrations when coadministered with a carbapenem; however, the specific consequences and subsequent therapy adjustments are not well described. We aimed to investigate the clinical and therapeutic implications of the carbapenem-valproate drug-drug interaction. Methods This retrospective analysis included data from 2 large academic medical centers during January 2017 to June 2022. The primary outcome was incidence of seizures or behavioral events stratified by valproate indication. All adult patient encounters with concomitant administration of any carbapenem antimicrobial and valproate were included. Patients without prolonged exposure to valproate prior to hospitalization, without valproate levels pre– and post–carbapenem administration, with an admitting diagnosis of seizure, with exposure to other agents that decrease valproate concentrations, or who had a seizure during the hospitalization prior to carbapenem exposure were excluded. Results Two hundred fifty-eight episodes of concomitant use among 78 unique adult patients were included. Valproate was used for seizure control in 41 patients (52.6%) and for mood-related disorders in 37 (47.4%). In those prescribed valproate for its antiepileptic properties, seizures occurred following carbapenem administration in 46.3% of encounters. In those taking valproate for mood-related disorders, 50.8% met the primary endpoint of behavioral disturbance. Conclusions Our study demonstrates significant clinical implications of the carbapenem-valproate interaction. Clinicians should be aware of this interaction and consider alternative antimicrobial and/or antiepileptic agents whenever possible. Adding or increasing doses of antiepileptic agents and/or consultation with a neurologist prior to concomitant use should be considered when this combination cannot be avoided. In this retrospective analysis, seizures and behavioral disturbances occurred following carbapenem administration in 46.3% and 50.8% of encounters, respectively, in patients with valproate exposure. Clinicians should be aware of this drug interaction and consider alternative antimicrobials when clinically appropriate.